Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib
Noelia Purroy, Yuzhou Evelyn Tong, Camilla K. Lemvigh, Nicoletta Cieri, Shuqiang Li, Erin M. Parry, Wandi Zhang, Laura Z. Rassenti, Thomas J. Kipps, Susan L. Slager, Neil E. Kay, Connie Lesnick, Tait D. Shanafelt, Paolo Ghia, Lydia Scarfò, Kenneth J. Livak, Peter V. Kharchenko, Donna S. Neuberg, Lars Rønn Olsen, Jean Fan, Satyen H. Gohil, Catherine J. Wu
Topics & Concepts
IbrutinibMedicineBruton's tyrosine kinaseImmunologyImmune systemImmune DysfunctionCancer researchLeukemiaChronic lymphocytic leukemiaRituximabLymphomaAntibodyDiseaseFludarabineChronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentImmunodeficiency and Autoimmune Disorders